Side-effects scale:31 Side-effects scale will be completed as a control check in medicated participants to ensure greater speed to diagnosis/medication normalisation is not off-set by greater side effects. SNAP-IV:32 The proportion of patients achieving selleck bio symptom normalisation assessed via the SNAP-IV. If the young person receives a QbTest on medication (Qb2), the timing on the 3-month SNAP-IV will be moved to coincide with Qb2 to provide a direct comparison of subjective (SNAP-IV) and objective (QbTest) measures. The SNAP-IV is a rating scale designed to assess ADHD symptoms. SDQ:30 The SDQ is a brief behavioural screening questionnaire
which can be used as part of a clinical assessment. C-GAS (Children’s Global Assessment
Scale33): Clinician opinion of patient outcome will be assessed via the C-GAS. The C-GAS is a 0–100 scale which that integrates psychological, social and academic functioning in children. EQ-5D-Y (EuroQol Five Dimensions Heath Questionnaire-Youth34): Child health-related quality of life will be assessed using the EQ-5D-Y. A resource collection profile tool will be used. It will encompass elements of a CSRI (Client Service Receipt Inventory35) often used in mental health studies but will be a specifically designed economic collection pro-forma for the purpose of this study. It will collect demographic details as well as information on all the services used by the child and family borne costs to be estimated. Indirect costs such as time lost from work incurred by the child’s parents or carers will further be recorded. This measure will enable a societal wide perspective for a cost-effectiveness analysis of the QbTest. The DAWBA29 QbTest22 SDQ30 Side-effects scale,31 SNAP-IV32 C-GAS33 EQ-5D-Y34 and CSRI35 all have established reliability, validity and history of use in
clinical and research settings. Feasibility and acceptability QbTest opinion questionnaire and interview: Clinician and patient opinion of the QbTest will be assessed via a questionnaire, developed by CLH and currently used to assess QbTest opinion in on-going studies at the Queens Medical Centre, Nottingham. This will provide information on the acceptability of QbTest in routine NHS settings. A subsample (n=20) of families and clinicians will be invited to participate in qualitative interviews to further AV-951 explore acceptability and feasibility of the QbTest. The subsample will be chosen at random from each participating site, using a random number generator. Table 1 displays a summary of measures, the informant and the time point of completion. All measures will have a 1-month window for completion, with the exception of the clinic pro-forma which must be completed during or just after the clinic appointment and the QbTest which must form part of the diagnostic or medication assessment.